Natus Medical Inc. (BABY) Releases Q4 Earnings Guidance
Natus Medical Inc. (NASDAQ:BABY) updated its fourth quarter earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of $0.52-0.55 for the period, compared to the Thomson Reuters consensus estimate of $0.48. The company issued revenue guidance of $107-109 million, compared to the consensus revenue estimate of $104.62 million.
A number of research firms have issued reports on BABY. Zacks Investment Research upgraded Natus Medical from a hold rating to a buy rating and set a $44.00 price target for the company in a research note on Thursday, July 7th. Benchmark Co. initiated coverage on Natus Medical in a research report on Tuesday, October 4th. They set a buy rating and a $55.00 price objective on the stock. Finally, Raymond James Financial Inc. raised Natus Medical from a market perform rating to an outperform rating and set a $46.00 price target on the stock in a report on Tuesday, September 13th.
Natus Medical Inc. (NASDAQ:BABY) opened at 39.70 on Wednesday. Natus Medical Inc. has a 12 month low of $29.54 and a 12 month high of $51.05. The company has a market cap of $1.29 billion, a P/E ratio of 34.22 and a beta of 0.78. The firm has a 50-day moving average price of $41.06 and a 200 day moving average price of $37.00.
Natus Medical (NASDAQ:BABY) last released its earnings results on Wednesday, October 19th. The company reported $0.39 earnings per share for the quarter, beating the consensus estimate of $0.34 by $0.05. The business had revenue of $90.90 million for the quarter, compared to the consensus estimate of $89.94 million. Natus Medical had a return on equity of 13.82% and a net margin of 10.20%. The business’s quarterly revenue was down 3.9% compared to the same quarter last year. During the same quarter last year, the business posted $0.39 earnings per share. Equities research analysts predict that Natus Medical Inc. will post $1.55 EPS for the current year.
In related news, insider James B. Hawkins acquired 10,000 shares of Natus Medical stock in a transaction that occurred on Wednesday, September 28th. The shares were purchased at an average price of $38.48 per share, for a total transaction of $384,800.00. Following the completion of the transaction, the insider now owns 459,725 shares in the company, valued at approximately $17,690,218. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.80% of the stock is owned by insiders.
A number of institutional investors have recently made changes to their positions in the company. Point72 Asset Management L.P. acquired a new stake in Natus Medical during the second quarter valued at about $23,534,000. Arizona State Retirement System boosted its stake in shares of Natus Medical by 1.8% in the second quarter. Arizona State Retirement System now owns 17,206 shares of the company’s stock worth $650,000 after buying an additional 300 shares during the last quarter. AHL Partners LLP boosted its stake in shares of Natus Medical by 733.7% in the second quarter. AHL Partners LLP now owns 78,697 shares of the company’s stock worth $2,974,000 after buying an additional 69,257 shares during the last quarter. AQR Capital Management LLC boosted its stake in shares of Natus Medical by 21.4% in the second quarter. AQR Capital Management LLC now owns 73,381 shares of the company’s stock worth $2,773,000 after buying an additional 12,913 shares during the last quarter. Finally, Teachers Retirement System of The State of Kentucky boosted its stake in shares of Natus Medical by 199.8% in the second quarter. Teachers Retirement System of The State of Kentucky now owns 35,380 shares of the company’s stock worth $1,337,000 after buying an additional 23,580 shares during the last quarter. Hedge funds and other institutional investors own 88.00% of the company’s stock.
About Natus Medical
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.
Receive News & Stock Ratings for Natus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Inc. and related stocks with our FREE daily email newsletter.